Counselors in Villas, NJ Accepting Medicare
9 Counselors found. Showing 1 - 9
 Angelina Montello Counselor Medicare: Not Enrolled in Medicare Practice Location: 128 Iowa Ave, Villas, NJ 08251 Phone: 609-972-4682 |
Mrs. Joanna Heather Little, LPC Counselor - Professional Medicare: Not Enrolled in Medicare Practice Location: 899 Bayshore Rd, Villas, NJ 08251 Phone: 609-886-8666 |
Nicole Sagan Farrell, M.A., LPC Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 899 Bayshore Road, Families Matter Llc, Villas, NJ 08251 Phone: 609-886-8666 |
Marguerite Brady, LPC, LCADC Counselor - Professional Medicare: Not Enrolled in Medicare Practice Location: 899 Bayshore Rd, Villas, NJ 08251 Phone: 609-886-8666 |
 Jon Little, CADC Counselor - Addiction (Substance Use Disorder) Medicare: Not Enrolled in Medicare Practice Location: 899 Bayshore Rd, Villas, NJ 08251 Phone: 609-886-8666 |
Kathryn Ann Gibson, MASTER OF ARTS Counselor Medicare: Not Enrolled in Medicare Practice Location: 899 Bayshore Rd, Villas, NJ 08251 Phone: 609-886-8666 Fax: 609-886-9666 |
Ms. Juana Maria Zegarra, LCSW Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 899 Bayshore Rd, Villas, NJ 08251 Phone: 609-886-8666 Fax: 609-886-9666 |
Kevin Gormley, ARNP Counselor - Mental Health Medicare: Medicare Enrolled Practice Location: 4006 Shore Dr, Villas, NJ 08251 Phone: 443-889-2600 |
Patricia M. Campbell, LPC, LCADC, CCS,ACS Counselor Medicare: Not Enrolled in Medicare Practice Location: 899 Bayshore Rd, Villas, NJ 08251 Phone: 609-886-8666 Fax: 609-886-9666 |
News Archive
Lab discovers way to keep short-lived catalysts active for longer than five months
Enzymes, the workhorses of chemical reactions in cells, lead short and brutal lives. They cleave and assemble proteins and metabolize compounds for a few hours, and then they are spent. This sad fact of nature has limited the possibilities of harnessing enzymes as catalytic tools outside the cell, in uses that range from biosensing to toxic waste cleanup.
Neurologix presents NLX-P101 Phase 2 trial in Parkinson's disease at 10th INS World Congress
Neurologix, Inc. announced the presentation today of efficacy results through one year of follow-up in patients treated as part of the Company's successful Phase 2 clinical trial for its novel, investigational gene therapy NLX-P101 for the treatment of Parkinson's disease.
Mylan introduces Cyclobenzaprine HCl ER Capsules, a muscle relaxant
Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has launched Cyclobenzaprine Hydrochloride (HCl) Extended-release (ER) Capsules, 15 mg and 30 mg. Mylan was the first company to have filed a substantially complete ANDA containing a Paragraph IV certification for Cyclobenzaprine HCl ER Capsules and was awarded 180 days of marketing exclusivity.
FDA approves Cardiva Medical's VASCADE Vascular Closure System
Cardiva Medical, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Premarket Approval (PMA) for the VASCADE Vascular Closure System (VCS).
› Verified 7 days ago